Andrew Satlin - Intracellular Executive Vice President and Chief Medical Officer
| ITCI Stock | USD 74.01 0.53 0.71% |
President
Mr. Andrew Satlin M.D. is the Executive Vice President and Chief Medical Officer of IntraCellular Therapies, Inc. Dr. Satlin has served as Executive Vice President and Chief Medical Officer of the Company since November 2017. From July 2008 to November 2017, Dr. Satlin served in a number of leadership positions at Eisai, Inc., most recently serving as Executive Vice President, Global Head of Medicine Creation Strategy, Neurology Business Group. Before joining Eisai, from 1997 to 2008, he served at Novartis in positions of increasing responsibility, including leadership of the Neurosciences regulatory group. Prior to joining Novartis, Dr. Satlin was an Assistant Professor of Psychiatry at Harvard Medical School. Dr. Satlin was also the Director of Geriatric Psychiatry and established a dementia clinic at McLean Hospital in Massachusetts. Dr. Satlin received his medical degree from Harvard Medical School and completed his residency in psychiatry and fellowship in geriatric psychiatry at McLean Hospital since 2017.
| Age | 62 |
| Tenure | 7 years |
| Address | 430 East 29th Street, New York, NY, United States, 10016 |
| Phone | 646 440 9333 |
| Web | https://www.intracellulartherapies.com |
Intracellular Management Efficiency
The company has return on total asset (ROA) of (0.1343) % which means that it has lost $0.1343 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2239) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.2. The current Return On Capital Employed is estimated to decrease to -0.28. As of now, Intracellular's Non Currrent Assets Other are increasing as compared to previous years. The Intracellular's current Deferred Long Term Asset Charges is estimated to increase to about 635.1 K, while Total Assets are projected to decrease to under 410.9 M.Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Craig Hopkinson | Alkermes Plc | 49 | |
| Payson Swaffield | Evotec SE ADR | 61 | |
| Michael Landine | Alkermes Plc | 70 | |
| CTodd Nichols | Alkermes Plc | N/A | |
| Rebecca Peterson | Alkermes Plc | 38 | |
| Mark Stejbach | Alkermes Plc | 55 | |
| David Gaffin | Alkermes Plc | 52 | |
| Shane Cooke | Alkermes Plc | 54 | |
| Adrian Hepner | Eagle Pharmaceuticals | 56 | |
| Elliot Ehrich | Alkermes Plc | 57 | |
| Mark Namchuk | Alkermes Plc | N/A | |
| Gordon Pugh | Alkermes Plc | 57 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 |
Intracellular Th Leadership Team
Elected by the shareholders, the Intracellular's board of directors comprises two types of representatives: Intracellular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intracellular. The board's role is to monitor Intracellular's management team and ensure that shareholders' interests are well served. Intracellular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intracellular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lawrence Wennogle, Vice President of Drug Discovery | ||
| Suresh Durgam, Senior Vice President Late Stage Clinical Development and Medical Affairs | ||
| Michael Rawlins, Director | ||
| Robert Nostrand, Independent Director | ||
| Richard Lerner, Director | ||
| Allen Fienberg, Co-Founder and VP of Bus. Devel. | ||
| Suresh MD, Executive Officer | ||
| Willie MD, Senior Development | ||
| Lawrence CPA, CFO, Finance | ||
| Kimberly Vanover, VP of Clinical Devel. | ||
| Michael Olchaskey, Senior Vice President Head of Regulatory Affairs | ||
| CPA CPA, CFO, Fin | ||
| Christopher Alafi, Director | ||
| Robert Davis, Senior Vice President and Chief Scientific Officer | ||
| Mark Neumann, Executive Vice President Chief Commercial Officer | ||
| Karen Esq, Senior Officer | ||
| Michael Halstead, Sr. VP, General Counsel and Secretary | ||
| Sharon Mates, Co-Founder, Chairman, CEO and Pres | ||
| Andrew Satlin, Executive Vice President and Chief Medical Officer | ||
| Michael JD, General VP | ||
| Juan Sanchez, Vice President - Corporate Communications and Investor Relations | ||
| Rory Riggs, Independent Director | ||
| John Bardi, Senior Vice President - Market Access, Policy and Government Affairs | ||
| Joel Marcus, Director | ||
| Lawrence Hineline, Vice President and CFO |
Intracellular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intracellular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 6.74 B | ||||
| Shares Outstanding | 97.48 M | ||||
| Shares Owned By Insiders | 2.49 % | ||||
| Shares Owned By Institutions | 98.60 % | ||||
| Number Of Shares Shorted | 3.47 M | ||||
| Price To Earning | (6.56) X |
Intracellular Investors Sentiment
The influence of Intracellular's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Intracellular. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Intracellular's public news can be used to forecast risks associated with an investment in Intracellular. The trend in average sentiment can be used to explain how an investor holding Intracellular can time the market purely based on public headlines and social activities around Intracellular Th. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intracellular's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intracellular's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Intracellular's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Intracellular.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intracellular in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intracellular's short interest history, or implied volatility extrapolated from Intracellular options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Intracellular Th information on this page should be used as a complementary analysis to other Intracellular's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Intracellular's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 4.843 | Quarterly Revenue Growth 0.503 | Return On Assets (0.13) | Return On Equity (0.22) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.